ExodusPoint Capital Management’s Kyntra Bio KYNB Stock Holding History

ExodusPoint Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-733	Closed	-$342K	–	1973
2023 Q1	$342K	Sell	733 -3,701	-83%	-$1.96M	﹤0.01%	1435
2022 Q4	$1.78M	Buy	+4,434	New	+$1.7M	0.03%	695
2022 Q2	–	Sell	-4,469	Closed	-$1.34M	–	2088
2022 Q1	$1.34M	Buy	4,469 +2,701	+153%	+$942K	0.02%	974
2021 Q4	$623K	Sell	1,768 -492	-22%	-$153K	0.01%	1280
2021 Q3	$577K	Buy	+2,260	New	+$801K	0.01%	1298
2021 Q2	–	Sell	-623	Closed	-$541K	–	2494
2021 Q1	$541K	Buy	+623	New	+$663K	0.01%	1292
2020 Q4	–	Sell	-235	Closed	-$242K	–	2088
2020 Q3	$242K	Buy	+235	New	+$253K	﹤0.01%	1389

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's KYNB Position: Q2 2023 in Review

ExodusPoint Capital Management sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 733 shares — an estimated $342K sold.

ExodusPoint Capital Management first reported a position in KYNB in Q3 2020 and held it in 7 quarters. The position peaked at $1.78M in Q4 2022. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

ExodusPoint Capital Management reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 733 Kyntra Bio shares in Q2 2023, an estimated $342K.
ExodusPoint Capital Management first reported a position in Kyntra Bio in Q3 2020 and held it in 7 quarters.
ExodusPoint Capital Management's Kyntra Bio position peaked at $1.78M in Q4 2022.
152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.